Paper23318436
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J and 2 others. Oncogene, 2013. Cited by 78 papers, by iCite.
Cite this record
ConductScience Library. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Papers, record 23318436. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23318436
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Immunologic Factors | Major topic |
| Neoplasms | Major topic |
| Thalidomide | Major topic |
| Animals | |
| Chromosome Deletion | |
| Chromosomes, Human, Pair 5 | |
| Epigenesis, Genetic | |
| Humans | |
| Immunomodulation | |
| Multiple Myeloma | |
| Myelodysplastic Syndromes |
Source PubMed
References144
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12173037 | Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. | Oncogene | 2002 | https://conductscience.org/library/papers/12173037 | PubMed |
| 2 | 18425106 | Up on the tightrope: natural killer cell activation and inhibition. | Nat Immunol | 2008 | https://conductscience.org/library/papers/18425106 | PubMed |
| 3 | 9499327 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. | Ann Intern Med | 1998 | https://conductscience.org/library/papers/9499327 | PubMed |
| 4 | 19966810 | A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. | Nat Med | 2010 | https://conductscience.org/library/papers/19966810 | PubMed |
| 5 | 10579967 | Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. | Gastroenterology | 1999 | https://conductscience.org/library/papers/10579967 | PubMed |
| 6 | 16940275 | Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16940275 | PubMed |
| 7 | 12036901 | Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. | Blood | 2002 | https://conductscience.org/library/papers/12036901 | PubMed |
| 8 | 22246035 | Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. | Blood | 2012 | https://conductscience.org/library/papers/22246035 | PubMed |
| 9 | 10229238 | Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. | Nat Med | 1999 | https://conductscience.org/library/papers/10229238 | PubMed |
| 10 | 20974848 | IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. | J Biol Chem | 2011 | https://conductscience.org/library/papers/20974848 | PubMed |
| 11 | 22241792 | Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22241792 | PubMed |
| 12 | 9249925 | Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo. | Teratog Carcinog Mutagen | 1997 | https://conductscience.org/library/papers/9249925 | PubMed |
| 13 | 11529908 | Deregulated cytokine network and defective Th1 immune response in multiple myeloma. | Clin Exp Immunol | 2001 | https://conductscience.org/library/papers/11529908 | PubMed |
| 14 | 22031859 | IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. | Blood | 2011 | https://conductscience.org/library/papers/22031859 | PubMed |
| 15 | 17576924 | Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. | Proc Natl Acad Sci U S A | 2007 | https://conductscience.org/library/papers/17576924 | PubMed |
| 16 | 21232561 | Functional modulation of AMP-activated protein kinase by cereblon. | Biochim Biophys Acta | 2011 | https://conductscience.org/library/papers/21232561 | PubMed |
| 17 | 8113151 | Expression of granule protein mRNAs in acute promyelocytic leukemia. | Hematol Pathol | 1993 | https://conductscience.org/library/papers/8113151 | PubMed |
| 18 | 9154767 | Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. | N Engl J Med | 1997 | https://conductscience.org/library/papers/9154767 | PubMed |
| 19 | 17234786 | Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. | Cancer Res | 2007 | https://conductscience.org/library/papers/17234786 | PubMed |
| 20 | 9988267 | The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. | Nat Genet | 1999 | https://conductscience.org/library/papers/9988267 | PubMed |
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42967027 | Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42967027 | PubMed |
| 42576759 | [Preliminary investigation into the mechanisms of thalidomide in inhibiting the malignant transformation of oral leukoplakia]. | Hua Xi Kou Qiang Yi Xue Za Zhi | 2026 | https://conductscience.org/library/papers/42576759 | PubMed |
| 42470200 | In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. | Chirality | 2026 | https://conductscience.org/library/papers/42470200 | PubMed |
| 41557108 | Disulfiram-induced c-FOS influences lipid metabolism and angiogenesis in hepatocellular carcinoma. | Sci China Life Sci | 2026 | https://conductscience.org/library/papers/41557108 | PubMed |
| 40322475 | Drug repurposing: Clinical practices and regulatory pathways. | Perspect Clin Res | 2025 | https://conductscience.org/library/papers/40322475 | PubMed |
| 39773053 | Strengthening Effect of Thalidomide Combined with an Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy. | Curr Pharm Biotechnol | 2025 | https://conductscience.org/library/papers/39773053 | PubMed |
| 38993289 | NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors. | Bladder Cancer | 2023 | https://conductscience.org/library/papers/38993289 | PubMed |
| 38817675 | (S)-3-aminopiperidine-2,6-dione is a biosynthetic intermediate of microbial blue pigment indigoidine. | mLife | 2022 | https://conductscience.org/library/papers/38817675 | PubMed |
| 38646175 | Inhibitors to degraders: Changing paradigm in drug discovery. | iScience | 2024 | https://conductscience.org/library/papers/38646175 | PubMed |
| 37111560 | Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37111560 | PubMed |
| 36289711 | Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury. | Biomedicines | 2022 | https://conductscience.org/library/papers/36289711 | PubMed |
| 36268122 | Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation. | ACS Pharmacol Transl Sci | 2022 | https://conductscience.org/library/papers/36268122 | PubMed |
| 35770527 | The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. | Haematologica | 2023 | https://conductscience.org/library/papers/35770527 | PubMed |
| 35247913 | AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35247913 | PubMed |
| 34834536 | Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. | J Pers Med | 2021 | https://conductscience.org/library/papers/34834536 | PubMed |
| 34085173 | Thalidomide Attenuates Colitis and Is Associated with the Suppression of M1 Macrophage Polarization by Targeting the Transcription Factor IRF5. | Dig Dis Sci | 2021 | https://conductscience.org/library/papers/34085173 | PubMed |
| 33907692 | TNFR2: Role in Cancer Immunology and Immunotherapy. | Immunotargets Ther | 2021 | https://conductscience.org/library/papers/33907692 | PubMed |
| 33860215 | N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. | ACS Pharmacol Transl Sci | 2021 | https://conductscience.org/library/papers/33860215 | PubMed |
| 33195898 | Lenalidomide (LENA) Hybrid Gold Complex Nanoparticles: Synthesis, Physicochemical Evaluation, and Perspectives in Nanomedicine. | ACS Omega | 2020 | https://conductscience.org/library/papers/33195898 | PubMed |
| 32906688 | Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in EZH2 Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32906688 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23318436
GET https://conductscience.org/api/papers/v1/23318436/references?page=2